These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10537443)

  • 1. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
    Chatterton ML; Scott-Lennox J; Wu AW; Scott J
    Pharmacoeconomics; 1999; 15 Suppl 1():67-74. PubMed ID: 10537443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
    Scott-Lennox JA; Mills RJ; Burt MS
    Ann Pharmacother; 1998 May; 32(5):525-30. PubMed ID: 9606471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
    Gatell J; Lange J; Gartland M
    Antivir Ther; 1999; 4(2):79-86. PubMed ID: 10682152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS; DeMasi R; Hill AM
    AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
    Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P
    AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.
    Lacey L; Gill MJ
    Pharmacoeconomics; 1999; 15 Suppl 1():13-22. PubMed ID: 10537439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.
    Petra Study Team
    Lancet; 2002 Apr; 359(9313):1178-86. PubMed ID: 11955535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
    Lacey L; Hopkinson PK; Montaner J; Leblanc F; Gill MJ
    Pharmacoeconomics; 1999; 15 Suppl 1():55-66. PubMed ID: 10537442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
    Dore GJ; Cooper DA; Barrett C; Goh LE; Thakrar B; Atkins M
    J Infect Dis; 1999 Sep; 180(3):607-13. PubMed ID: 10438346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
    Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
    Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.